pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Yervoy · news · pharmadog
← back to Yervoy
News mentioning Yervoy
13
stories
27d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
29d
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 28, 26
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
Jul 23, 26
Scancell to go public after winning reverse merger bid for troubled Neuphoria
fiercebiotech
May 8, 26
Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
